Dr Reddy’s hits a 52-week low after weak Q1 earnings, Semaglutide API issues and Middle East costs trigger target cuts; read the outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results